Ming-Wen Hu

Ming-Wen Hu

Auto-generated profile, based on publicly available information

Ming-Wen Hu

Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JZJing Zhang
Jing Zhang
DSDeepti Sharma
Deepti Sharma
ADAumreetam Dinabandhu
Aumreetam Dinabandhu
JSJaron Sanchez
Jaron Sanchez
BABrooks Applewhite
Brooks Applewhite
ASAkrit Sodhi
Akrit Sodhi
Many patients with diabetic eye disease respond inadequately to anti-VEGF therapies, implicating additional vasoactive mediators in its pathogenesis. We demonstrate that levels of angiogenic proteins regulated by HIF-1 and -2 remain elevated in the eyes of people with diabetes despite treatment with anti-VEGF therapy. Conversely, by inhibiting HIFs, we normalized the expression of multiple vasoactive mediators in mouse models of diabetic eye disease. Accumulation of HIFs and HIF-regulated vasoactive mediators in hyperglycemic animals was observed in the absence of tissue hypoxia, suggesting that targeting HIFs may be an effective early treatment for diabetic retinopathy. However, while the HIF inhibitor acriflavine prevented retinal vascular hyperpermeability in diabetic mice for several months following a single intraocular injection, accumulation of acriflavine in the retina resulted in retinal toxicity over time, raising concerns for its use in patients. Conversely, 32-134D, a recently developed HIF inhibitor structurally unrelated to acriflavine, was not toxic to the retina, yet effectively inhibited HIF accumulation and normalized HIF-regulated gene expression in mice and in human retinal organoids. Intraocular administration of 32-134D prevented retinal neovascularization and vascular hyperpermeability in mice. These results provide the foundation for clinical studies assessing 32-134D for the treatment of patients with diabetic eye disease.

28 November 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
XWXuewei Wang
Xuewei Wang
SYShu-Guang Yang
Shu-Guang Yang
MHMing-Wen Hu
Ming-Wen Hu
RWRui-Ying Wang
Rui-Ying Wang
CZChi Zhang
Chi Zhang
FZFengquan Zhou
Fengquan Zhou
Current treatments for neurodegenerative diseases and neural injuries face major challenges, primarily due to the diminished regenerative capacity of neurons in the mammalian CNS as they mature. Here, we investigated the role of Ezh2, a histone methyltransferase, in regulating mammalian axon regeneration. We found that Ezh2 declined in the mouse nervous system during maturation but was upregulated in adult dorsal root ganglion neurons following peripheral nerve injury to facilitate spontaneous axon regeneration. In addition, overexpression of Ezh2 in retinal ganglion cells in the CNS promoted optic nerve regeneration via both histone methylation–dependent and –independent mechanisms. Further investigation revealed that Ezh2 fostered axon regeneration by orchestrating the transcriptional silencing of genes governing synaptic function and those inhibiting axon regeneration, while concurrently activating various factors that support axon regeneration. Notably, we demonstrated that GABA transporter 2, encoded by Slc6a13, acted downstream of Ezh2 to control axon regeneration. Overall, our study underscores the potential of modulating chromatin accessibility as a promising strategy for promoting CNS axon regeneration.

18 January 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
XCXuan Cao
Xuan Cao
JSJaron Sanchez
Jaron Sanchez
ADAumreetam Dinabandhu
Aumreetam Dinabandhu
CGChuanyu Guo
Chuanyu Guo
TPTapan P. Patel
Tapan P. Patel
ASAkrit Sodhi
Akrit Sodhi
Background. To reduce the treatment burden for patients with neovascular age-related macular degeneration (nvAMD), emerging therapies targeting vascular endothelial growth factor (VEGF) are being designed to extend the interval between treatments, thereby minimizing the number of intraocular injections. However, which patients will benefit from longer-acting agents is not clear. Methods. Eyes with nvAMD (n = 122) underwent 3 consecutive monthly injections with currently available anti-VEGF therapies, followed by a treat-and-extend protocol. Patients who remained quiescent 12 weeks from their prior treatment entered a treatment pause and were switched to pro re nata (PRN) treatment (based on vision, clinical exam, and/or imaging studies). Proteomic analysis was performed on aqueous fluid to identify proteins that correlate with patients’ response to treatment. Results. At the end of 1 year, 38 of 122 eyes (31%) entered a treatment pause (≥30 weeks). Conversely, 21 of 122 eyes (17%) failed extension and required monthly treatment at the end of year 1. Proteomic analysis of aqueous fluid identified proteins that correlated with patients’ response to treatment, including proteins previously implicated in AMD pathogenesis. Interestingly, apolipoprotein-B100 (ApoB100), a principal component of drusen implicated in the progression of nonneovascular AMD, was increased in treated patients who required less frequent injections. ApoB100 expression was higher in AMD eyes compared with controls but was lower in eyes that develop choroidal neovascularization (CNV), consistent with a protective role. Accordingly, mice overexpressing ApoB100 were partially protected from laser-induced CNV. Funding. This work was supported by the National Eye Institute, National Institutes of Health grants R01EY029750, R01EY025705, and R01 EY27961; the Research to Prevent Blindness, Inc.; the Alcon Research Institute; and Johns Hopkins University through the Robert Bond Welch and Branna and Irving Sisenwein professorships in ophthalmology. Conclusion. Aqueous biomarkers could help identify patients with nvAMD who may not require or benefit from long-term treatment with anti-VEGF therapy.

13 April 2023 in Cells
Verified
Journal Article
Open access
PDF file
SSSrinivasa R. Sripathi
Srinivasa R. Sripathi
MHMing-Wen Hu
Ming-Wen Hu
RTRavi Chakra Turaga
Ravi Chakra Turaga
RMRebekah Mikeasky
Rebekah Mikeasky
GSGanesh Satyanarayana
Ganesh Satyanarayana
DZDonald J. Zack
Donald J. Zack
Epithelial-mesenchymal transition (EMT), which is well known for its role in embryonic development, malignant transformation, and tumor progression, has also been implicated in a variety of retinal diseases, including proliferative vitreoretinopathy (PVR), age-related macular degeneration (AMD), and diabetic retinopathy. EMT of the retinal pigment epithelium (RPE), although important in the pathogenesis of these retinal conditions, is not well understood at the molecular level. We and others have shown that a variety of molecules, including the co-treatment of human stem cell-derived RPE monolayer cultures with transforming growth factor beta (TGF–β) and the inflammatory cytokine tumor necrosis factor alpha (TNF–α), can induce RPE–EMT; however, small molecule inhibitors of RPE–EMT have been less well studied. Here, we demonstrate that BAY651942, a small molecule inhibitor of nuclear factor kapa-B kinase subunit beta (IKKβ) that selectively targets NF-κB signaling, can modulate TGF–β/TNF–α-induced RPE–EMT. Next, we performed RNA-seq studies on BAY651942 treated hRPE monolayers to dissect altered biological pathways and signaling events. Further, we validated the effect of IKKβ inhibition on RPE–EMT-associated factors using a second IKKβ inhibitor, BMS345541, with RPE monolayers derived from an independent stem cell line. Our data highlights the fact that pharmacological inhibition of RPE–EMT restores RPE identity and may provide a promising approach for treating retinal diseases that involve RPE dedifferentiation and EMT.

23 April 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
MHMing-Wen Hu
Ming-Wen Hu
DKDong Won Kim
Dong Won Kim
SLSheng Liu
Sheng Liu
DZDonald J. Zack
Donald J. Zack
SBSeth Blackshaw
Seth Blackshaw
JQJiang Qian
Jiang Qian
Single-cell RNA-sequencing (scRNA-seq) provides new opportunities to gain a mechanistic understanding of many biological processes. Current approaches for single cell clustering are often sensitive to the input parameters and have difficulty dealing with cell types with different densities. Here, we present Panoramic View (PanoView), an iterative method integrated with a novel density-based clustering, Ordering Local Maximum by Convex hull (OLMC), that uses a heuristic approach to estimate the required parameters based on the input data structures. In each iteration, PanoView will identify the most confident cell clusters and repeat the clustering with the remaining cells in a new PCA space. Without adjusting any parameter in PanoView, we demonstrated that PanoView was able to detect major and rare cell types simultaneously and outperformed other existing methods in both simulated datasets and published single-cell RNA-sequencing datasets. Finally, we conducted scRNA-Seq analysis of embryonic mouse hypothalamus, and PanoView was able to reveal known cell types and several rare cell subpopulations. Author summary: One of the important tasks in analyzing single-cell transcriptomics data is to classify cell subpopulations. Most computational methods require users to input parameters and sometimes the proper parameters are not intuitive to users. Hence, a robust but easy-to-use method is of great interest. We proposed PanoView algorithm that utilizes an iterative approach to search cell clusters in an evolving three-dimension PCA space. The goal is to identify the cell cluster with the most confidence in each iteration and repeat the clustering algorithm with the remaining cells in a new PCA space. To cluster cells in a given PCA space, we also developed OLMC clustering to deal with clusters with varying densities. We examined the performance of PanoView in comparison to other existing methods using ten published single-cell datasets and simulated datasets as the ground truth. The results showed that PanoView is an easy-to-use and reliable tool and can be applied to diverse types of single-cell RNA-sequencing datasets.